Pan-Canadian Oncology Drug Review (pCODR): Patient & Caregiver Perspectives (2 surveys)

We are looking for input from patients & caregivers with experience with metastatic colorectal cancer to complete one or both of the surveys below. They should take approximately 20 minutes to complete.

The results will be used as part of Colorectal Cancer Canada’s (CCC’s) Patient Evidence Submission to the pan-Canadian Oncology Drug Review (pCODR). Your feedback is extremely important and, although there is no guarantee, it may help to improve access to this therapy for patients in Canada.

We will also be conducting short interviews to hear individual experiences to help better understand how these combination therapies meet the needs and preferences of patients, caregivers, and families. If you have received: first-line panitumumab plus chemotherapy for left-sided primary tumours, OR trifluridine/tipiracil (Lonsurf) plus bevacizumab, and are willing to participate in an interview, please get in touch with our support team by email: support@colorectalcancercanada.com.

LONSURF SURVEY

The drug therapy under review by pCODR is Trifluridine and Tipiracil (Lonsurf^®) plus bevacizumab for the third or fourth line treatment of metastatic colorectal cancer (mCRC) patients who have been previously treated with standard of care therapies (which may include FOLFOX, FOLFIRI, bevacizumab, panitumumab (Vectibix^®), and cetuximab (Erbitux^®)). Your feedback is extremely important and, although there is no guarantee, it may help to improve access to this therapy for patients in Canada

PANITUMUMAB SURVEY

The drug therapy under review by pCODR is panitumumab in combination with chemotherapy for the first-line treatment of mCRC patients with left-sided primary tumours that express wild-type (WT) RAS. Your feedback is extremely important and, although there is no guarantee, it may help to improve access to this therapy for patients in Canada.